Half Yearly Report

RNS Number : 4274S
Judges Scientific PLC
24 September 2014
 

 

Judges Scientific plc

("Judges Scientific", the "Company", or the "Group")

 

Interim results for the six months ended 30 June 2014

 

JUDGES SCIENTIFIC REPORTS RECORD HALF-YEAR RESULTS

 

 

Highlights:

 

·       Revenues up 43% to a record £21.9 million (H1-2013: £15.4 million) including 3.2% organic growth

·       Adjusted* pre-tax profit up 30% to a record £4.1 million (H1-2013: £3.1 million)

·       Adjusted* basic earnings per share up 22% to a record 50.3p (H1-2013: 41.1p)

·       Interim dividend of 7.3p, an increase of 10.6% (H1-2013: 6.6p); covered seven times by adjusted earnings

·       Adjusted* net debt of £3.3 million at 30 June 2014 (30 June 2013: £15 million and 31 December 2013: £5.7 million)

·       Cash balances of £10.1 million at 30 June 2014

.     Organic order intake down 4.8% compared with H1-2013

 

 

* Adjusted earnings figures are stated after adding back exceptional items relating to derivative financial instruments, hedging of risks materialising after the end of the period, amortisation of intangible assets and acquisition-related costs. Adjusted net debt notionally includes acquisition-related payments which had yet to be settled at the balance sheet date and excludes subordinated debt owed by subsidiaries to minority shareholders.

 

 

Alex Hambro, Chairman of Judges Scientific, commented:

 

"I am able to announce a record set of interim results for the ninth consecutive year. As indicated in our trading statement in July, progress at the mid-year has been driven by Scientifica's contribution, with only modest organic growth. The business climate within the instrumentation sector remains challenging but your Group's ability to pursue its strategic objectives is undiminished."

 

For further information please contact:

 

 

Judges Scientific plc

David Cicurel, CEO

 

+44 (0) 1342 323 600

 

Shore Capital (Nomad and Broker)

Pascal Keane

Edward Mansfield

 

 +44 (0) 20 7408 4090

 

Cardew Group

Nadja Vetter

+44 (0) 20 7930 0777

+44 (0) 7941 340 436

 

 

 

Website:

Judges Scientific: www.judges.uk.com

Chairman's Statement

 

For the ninth consecutive year, I am able to announce progress at the interim stage with revenues, adjusted operating profits, earnings per share and dividends all at record levels.

 

Revenues for the six months ended 30 June 2014 rose 43% to £21.9 million (H1-2013: £15.4 million); the businesses which were owned by the Group on 1 January 2013 achieved organic growth of 3.2%, with weak performances in China and the US (each down 15%) counterbalanced by 10% growth in all other territories. The remainder of the increase reflected the first-time inclusion of a full six months of revenues from Scientifica, the specialist manufacturer of electrophysiology equipment acquired by the Group in June 2013.

 

Adjusted pre-tax profit for the first half of 2014 rose 30% to £4.1 million (H1-2013: £3.1 million). The increase was attributable to the inclusion of the Scientifica figures, with organic EBITA contribution from businesses which were owned by the Group on 1 January 2013 remaining static compared with the first half of 2013.

 

Earnings per share progressed despite the 11% increase in our issued share capital, 9.4% of which resulted from the £8.1 million equity placing in October 2013. Adjusted basic earnings per share rose 22% to 50.3p (H1-2013: 41.1p). Adjusted diluted earnings per share increased 24% to 48.7p (H1-2013: 39.4p). The return on total invested capital ("ROTIC") decreased from 41% to 30%, as was anticipated at the time of the Scientifica acquisition.

 

As in the past, the Group's figures have been adjusted to eliminate items which have to be included in the accounts under IFRS but which, in the opinion of the Directors, serve to obscure rather than clarify the Group's trading performance.  The most significant item during this half-year was the amortisation of intangible assets (£2.2 million). After the period end, the remaining Convertible Redeemable shares were converted and as a result the 2015 IFRS results will be free from this distortion. The IFRS-related charges reduced profit before tax from £4.1 million to £1.9 million (H1-2013: £777,000) and earnings per share to 22.2p basic and 21.6 diluted (H1-2013: 7p basic and 6.7p diluted).

 

Organic order intake during the six-month period decreased 4.8% compared to the first half of 2013; total order intake (including Scientifica) was 11% below the level required to meet the Group's sales budget without consuming its order book. The second quarter showed a moderate but insufficient improvement compared to the first. The order book at 30 June 2014 represented 7.8 weeks of sales, compared to 10.6 weeks at 30 June 2013.

 

Cash flow during the first half was strong, with cash from operations representing 76% of adjusted EBIT; this resulted in a 42% reduction in adjusted net debt to £3.3 million (2013: £15 million on 30 June and £5.7 million at the year-end). Cash balances at the end of the period exceeded £10.1 million.

 

The Company's dividend policy is to achieve steady increases in payments, with a step change provided this does not impair the visibility of future progression. Consistent with this policy and taking into account the challenging business environment, the Board has concluded that it can prudently declare an interim dividend of 7.3p (2013: 6.6p), which will be paid on Friday 7 November 2014 to shareholders on the register on Friday 10 October 2014. The shares will go ex-dividend on Thursday 9 October 2014.

 

Trading at the start of the second half has continued to be difficult. Weekly order intake in the third quarter has broadly mirrored the activity seen in the first half.

 

The principal drivers of shareholder value creation have been our ability to deliver net debt reduction, a progressive dividend policy and the completion of earnings-enhancing acquisitions. In spite of the frustrations encountered during the first half of 2014, your Group's ability to deliver these objectives remains undiminished.

 

The Hon. Alexander Hambro

Chairman

24 September 2014

 

JUDGES SCIENTIFIC plc

 

CONDENSED CONSOLIDATED INTERIM STATEMENT OF COMPREHENSIVE INCOME

Unaudited




6 months to 30 June 2014

6 months to 30 June 2013

Year to 31 December 2013


Note

£000

£000

£000

£000

£000



Before exceptional items

Exceptional items

Total



Revenue


21,927

-

21,927

15,351

36,041

Operating costs excluding exceptional items


(17,533)

-

(17,533)

(12,054)

(28,228)

Operating profit excluding exceptional items


4,394

-

4,394

3,297

7,813

Exceptional items







Amortisation of intangible assets

5

-

(2,185)

(2,185)

(1,250)

(4,498)

Contingent consideration measured at fair value


-

(16)

(16)

(38)

(317)

Financial instruments measured at fair value







Hedging contracts


-

7

7

(174)

24

Convertible Redeemable shares


-

(12)

(12)

(111)

(340)

Relocation costs


-

-

-

-

(158)

Acquisition costs


-

-

-

(794)

(794)

Operating profit/(loss)


4,394

(2,206)

2,188

930

1,730

Interest receivable


9

-

9

5

6

Interest payable


(305)

-

(305)

(158)

(497)

Profit/(loss) before tax


4,098

(2,206)

1,892

777

1,239

Taxation (charge)/credit


(920)

476

(444)

(364)

102

Profit/(loss) and total comprehensive income for the period


3,178

(1,730)

1,448

413

1,341

Attributable to:







Equity holders of the parent company


2,973

(1,662)

1,311

372

1,266

Non-controlling interest


205

(68)

137

41

75








Earnings per share - total and continuing (including exceptional items)

Pence

Pence

Pence

Basic

6



22.2

Diluted

6



21.6

Earnings per share - total and continuing (excluding exceptional items)




Basic

6



50.3

Diluted

6



48.7

 

There are no items of other comprehensive income for the three periods in question.

The accompanying notes form an integral part of these consolidated financial statements.

 

JUDGES SCIENTIFIC plc

 

CONDENSED CONSOLIDATED INTERIM BALANCE SHEET

 

Unaudited


30 June

2014

30 June

2013

31 December

2013


Note

£000

£000

£000






ASSETS





Non-current assets





Property, plant and equipment


4,546

4,286

4,695

Goodwill


8,678

8,678

8,678

Other intangible assets

5

10,728

16,161

12,913








23,952

29,125

26,286






Current assets





Inventories


5,926

5,757

5,824

Trade and other receivables


6,960

6,244

6,547

Cash and cash equivalents


10,129

2,758

10,054








23,015

14,759

22,425






Total assets


46,967

43,884

48,711






LIABILITIES





Current liabilities





Trade and other payables


(5,387)

(6,350)

(6,075)

Derivative financial instruments - Convertible Redeemable shares


(585)

(345)

(574)

Trade and other payables relating to acquisitions


(155)

(3,079)

(1,554)

Current portion of long-term borrowings


(4,039)

(3,449)

(4,043)

Current tax payable


(1,521)

(1,438)

(1,320)








(11,687)

(14,661)

(13,566)






Non-current liabilities





Long-term borrowings


(9,759)

(12,350)

(11,547)

Deferred tax liabilities


(2,228)

(3,664)

(2,704)








(11,987)

(16,014)

(14,251)






Total liabilities


(23,674)

(30,675)

(27,817)






Net assets


23,293

13,209

20,894






EQUITY





Share capital


298

266

293

Share premium


14,255

6,473

14,186

Capital redemption reserve


22

22

22

Merger reserve


1,352

475

475

Retained earnings


6,946

5,626

5,635






Equity attributable to equity holders of the parent company


22,873

12,862

20,611






Non-controlling interest


420

347

283






Total equity


23,293

13,209

20,894

 



 

JUDGES SCIENTIFIC plc

 

CONDENSED CONSOLIDATED INTERIM STATEMENT OF CHANGES IN EQUITY

 

Unaudited


Share capital

Share premium

Capital redemption reserve

Merger reserve

Retained earnings

Total *

Non-

controlling

interest

Total equity


Note

£000

£000

£000

£000

£000

£000

£000

£000

Balance at

1 January 2014


293

14,186

22

475

5,635

20,611

283

20,894

Issue of share capital

7

5

69

-

877

-

951

-

951

Transactions with owners


5

69

-

877

-

951

-

951

Profit for the period


-

-

-

-

1,311

1,311

137

1,448

Total comprehensive income for the period


-

-

-

-

1,311

1,311

137

1,448

Balance at

30 June 2014


298

14,255

22

1,352

6,946

22,873

420

23,293

 



Share capital

Share premium

Capital redemption reserve

Merger reserve

Retained earnings

Total *

Non-

controlling

interest

Total equity


Note

£000

£000

£000

£000

£000

£000

£000

£000

Balance at

1 January 2013


265

6,467

22

475

5,254

12,483

306

12,789

Issue of share capital


1

6

-

-

-

7

-

7

Transactions with owners


1

6

-

-

-

7

-

7

Profit for the period


-

-

-

-

372

372

41

413

Total comprehensive income for the period


-

-

-

-

372

372

41

413

Balance at

30 June 2013


266

6,473

22

475

5,626

12,862

347

13,209

 



Share capital

Share premium

Capital redemption reserve

Merger reserve

Retained earnings

Total *

Non-

controlling

interest

Total equity


Note

£000

£000

£000

£000

£000

£000

£000

£000

Balance at

1 January 2013


265

6,467

22

475

5,254

12,483

306

12,789

Dividends


-

-

-

-

(885)

(885)

(98)

(983)

Issue of share capital


28

7,719

-

-

-

7,747

-

7,747

Transactions with owners


28

7,719

-

-

(885)

6,862

(98)

6,764

Profit for the period


-

-

-

-

1,266

1,266

75

1,341

Total comprehensive income for the period


-

-

-

-

1,266

1,266

75

1,341

Balance at

31 December 2013


293

14,186

22

475

5,635

20,611

283

20,894

 

*  -  Total represents amounts attributable to equity holders of the parent company

 



JUDGES SCIENTIFIC plc

 

CONDENSED CONSOLIDATED INTERIM CASH FLOW STATEMENT

 

Unaudited


6 months to

30 June

2014

6 months to

30 June

2013

Year to

31 December

2013


Note

£000

£000

£000

Cash flows from operating activities





Profit after tax


1,448

413

1,341

Adjustments for:





Financial instruments measured at fair value





Hedging contracts


(7)

134

(24)

Convertible Redeemable shares


12

111

340

Contingent consideration measured at fair value


16

38

317

Depreciation


193

111

292

Amortisation of intangible assets

5

2,185

1,250

4,498

(Profit)/loss on disposal of property, plant and equipment


(13)

8

18

Foreign exchange (gains)/losses on foreign currency loans


(19)

142

127

Interest receivable


(9)

(5)

(6)

Interest payable


305

158

497

Tax expense recognised in income statement


444

404

(102)

Increase in inventories


(102)

(715)

(783)

Increase in trade and other receivables


(406)

(519)

(798)

Decrease in trade and other payables


(714)

(291)

(709)

Cash generated from operations


3,333

1,239

5,008

Interest paid


(305)

(153)

(497)

Tax paid


(719)

(227)

(840)

Net cash from operating activities


2,309

859

3,671






Cash flows from investing activities





Paid on acquisition of new subsidiaries


(500)

(12,000)

(13,400)

Gross cash inherited on acquisition


-

1,772

1,772

Acquisition of subsidiaries, net of cash acquired


(500)

(10,228)

(11,628)

Paid on the acquisition of trade and assets


(22)

(57)

(91)

Purchase of property, plant and equipment


(31)

(1,481)

(2,080)

Interest received


9

5

6

Net cash used in investing activities


(544)

(11,761)

(13,793)






Cash flows from financing activities





Proceeds from issue of share capital


72

7

7,747

Repayments of borrowings


(1,762)

(765)

(1,776)

Proceeds from bank loans


-

9,000

9,770

Dividends paid - equity shareholders


-

-

(885)

Dividends paid - non controlling interests in subsidiary


-

-

(98)

Net cash from financing activities


(1,690)

8,242

14,758






Net increase/(decrease) in cash and cash equivalents


75

(2,660)

4,636

Cash and cash equivalents at beginning of period


10,054

5,418

5,418

Cash and cash equivalents at end of period


10,129

2,758

10,054



 

JUDGES SCIENTIFIC plc

 

NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

 

 

1.         Nature of operations

 

Judges Scientific plc is the ultimate parent company of the Group, whose principal activities comprise the design, manufacture and sale of scientific instruments.  The subsidiaries are grouped into two segments.

 

·      Material Sciences Group

·        Fire Testing Technology Limited is the world's major producer of instruments designed to measure the reaction of materials to fire; the activity is supported through the in-house production of engineering parts by its subsidiary company, Aitchee Engineering Limited.  Its other trading subsidiary, Sircal Instruments (UK) Limited, designs, manufactures and sells rare gas purifiers for use in metals analysis.

·        PE.fiberoptics Limited is a significant provider to the telecoms industry of equipment to test the properties of fibre optic and fibre optic networks.

·        Global Digital Systems Limited designs, develops and manufactures equipment and software used for the computer-controlled testing of soils and rocks.

 

·      Vacuum Group

·        Quorum Technologies Limited designs, manufactures and sells instruments that prepare samples for examination in electron microscopes.

·        UHV Design Limited designs, manufactures and sells instruments to create motion, heating and cooling within ultra high vacuum chambers.

·        Deben UK Limited designs, manufactures and sells devices used to enable or to improve the observation of objects under microscopes.

·        Scientifica Limited designs, manufactures and sells complete instrument rigs used in electrophysiology, comprised of micromanipulators, optical microscopes and associated mounting solutions.

 

 

2.         General information and basis of preparation

 

The financial information set out in these condensed consolidated interim financial statements for the six months ended 30 June 2014 and the comparative figures for the six months ended 30 June 2013 are unaudited.  They have been prepared taking into account the requirements of IAS 34 Interim Financial Reporting and the AIM Rules.  They do not contain all the information required for full annual financial statements and should be read in conjunction with the consolidated financial statements of the Group for the year ended 31 December 2013, which have been prepared in accordance with IFRS as adopted by the European Union.

 

The financial information for the year ended 31 December 2013 set out in this interim report does not constitute statutory accounts as defined in section 434 of the Companies Act 2006.  The Group's statutory financial statements for the year ended 31 December 2013 have been filed with the Registrar of Companies.  The Auditor's Report in respect of those financial statements was unqualified and did not contain statements under section 498 of the Companies Act 2006.

 

The condensed consolidated interim financial statements are presented in Sterling, which is also the functional currency of the parent company.

 

Judges Scientific plc is the Group's ultimate parent company.  The Company is a Public Limited Company incorporated and domiciled in the United Kingdom.  Its registered office and principal place of business is Unit 19, Charlwoods Road, East Grinstead, West Sussex RH19 2HL.  Its shares are listed on the Alternative Investment Market.

 

The condensed consolidated interim financial statements have been approved for issue by the Board of Directors on 23 September 2014.

 

3.         Significant accounting policies

 

The condensed consolidated interim financial statements have been prepared in accordance with the accounting policies adopted in the last annual financial statements for the year ended 31 December 2013, except for the taxation policy where, for the purposes of the interims, the tax charge on underlying business performance is calculated by reference to the estimated effective rate for the full year.

 

The accounting policies have been applied consistently throughout the Group for the purposes of preparation of these condensed consolidated interim financial statements.

 

 

4.         Significant events and transactions

 

Revenues for the six months ended 30 June 2014 rose strongly to £21.9m, up 43% on the equivalent period in the previous year.  This increase was largely attributable to the inclusion of Scientifica Limited (acquired on 26 June 2013), with organic revenue growth achieved by the other operating companies in the Group amounting to 3.2%.  Similarly the 30% increase in adjusted pre-tax profits was attributable to the inclusion of Scientifica, with static results overall from the other operating companies.

 

Order intake during the first half of the financial year for the businesses which were owned by the Group on 1 January 2013 was disappointing, with a shortfall of 4.8% compared with the equivalent figures for the previous period.  Order intake in the third quarter has broadly mirrored the activity seen in the first half.

 

 

5.         Intangible assets

 

The following tables show the significant additions to and amortisation of intangible assets:

 


Carrying amount at

1 January 2014

Additions

Amortisation

Carrying

amount at

30 June 2014


£000

£000

£000

£000






Distribution agreements

866

-

152

714

Research and development

3,067

-

441

2,626

Customer relationships

3,352

-

875

2,477

Brand and domain names

5,628

-

717

4,911



-



Total

12,913

-

2,185

10,728

 


Carrying

amount at

1 January 2013

Additions

Amortisation

Carrying

amount at

30 June 2013


£000

£000

£000

£000






Non-competition agreements

49

-

49

-

Distribution agreements

693

430

105

1,018

Research and development

2,296

1,508

293

3,511

Customer relationships

1,890

3,001

526

4,365

Sales order backlog

-

921

-

921

Brand and domain names

2,167

4,456

277

6,346






Total

7,095

10,316

1,250

16,161

 


Carrying

amount at

1 January 2013

Additions

Amortisation

Carrying

amount at

31 December

2013


£000

£000

£000

£000






Non-competition agreements

49

-

49

-

Distribution agreements

693

430

257

866

Research and development

2,296

1,508

737

3,067

Customer relationships

1,890

3,001

1,539

3,352

Sales order backlog

-

921

921

-

Brand and domain names

2,167

4,456

995

5,628






Total

7,095

10,316

4,498

12,913

 



 

 

6.         Earnings per share

 

Basic earnings per share is calculated on the earnings attributable to Ordinary shareholders divided by the weighted average number of shares in issue during the period.

 

Diluted earnings per share is calculated on the basic earnings per share, adjusted to allow for the issue of shares on the assumed conversion of all dilutive options and other dilutive potential Ordinary shares.  The calculation is based on the treasury method prescribed in IAS 33.  This calculates the theoretical number of shares that could be purchased at the average middle market price in the period out of the proceeds of the notional exercise of outstanding options.  The difference between this theoretical number and the actual number of shares under option is deemed liable to be issued at nil value and represents the dilution.

 

Reconciliations of the earnings and the weighted average number of shares used in the calculations are set out below:

 

6 months to 30 June 2014

Earnings attributable to equity holders of the parent company

Weighted
average
number of
shares

Earnings
per
share


£000

no.

Pence





Profit after tax including exceptional items for calculation of basic and diluted earnings per share

1,311



Add-back exceptional items net of tax and non-controlling interest, as applicable:




Charge/(gain) relating to derivative financial instruments




Hedging contracts

(5)



Convertible Redeemable shares

12



Contingent consideration measured at fair value

16



Amortisation of intangible assets

1,639



Basic and diluted profit after tax, excluding exceptional items

2,973







Number of shares for calculation of basic earnings per share including exceptional items


5,914,964


Dilutive effect of potential shares


164,889


Number of shares for calculation of diluted earnings per share including exceptional items


6,079,853


Dilutive effect of potential derivative financial instruments


29,263


Number of shares for calculation of diluted earnings per share excluding exceptional items


6,109,116






Basic earnings per share (including exceptional items)



22.2

Diluted earnings per share (including exceptional items)



21.6

Basic earnings per share (excluding exceptional items)



50.3

Diluted earnings per share (excluding exceptional items)



48.7

 

 

6 months to 30 June 2013

Earnings attributable to equity holders of the parent company

Weighted
average
number of
shares

Earnings
per
share


£000

no.

Pence





Profit after tax including exceptional items for calculation of basic and diluted earnings per share

372



Add-back exceptional items net of tax and non-controlling interest, as applicable:




Charge relating to derivative financial instruments




Hedging contracts

134



Convertible Redeemable shares

111



Contingent consideration measured at fair value

38



Amortisation of intangible assets

816



Acquisition-related transaction costs

716



Basic and diluted profit after tax, excluding exceptional items

2,187







Number of shares for calculation of basic earnings per share including exceptional items


5,316,411


Dilutive effect of potential shares


213,063


Number of shares for calculation of diluted earnings per share including exceptional items


5,529,474


Dilutive effect of potential derivative financial instruments


25,439


Number of shares for calculation of diluted earnings per share excluding exceptional items


5,554,913






Basic earnings per share (including exceptional items)



7.0

Diluted earnings per share (including exceptional items)



6.7

Basic earnings per share (excluding exceptional items)



41.1

Diluted earnings per share (excluding exceptional items)



39.4

 

 

 

Year to 31 December 2013

Earnings attributable to equity holders of the parent company

Weighted
average
number of
shares

Earnings
per
share


£000

no.

Pence





Profit after tax including exceptional items for calculation of basic and diluted earnings per share

1,266



Add-back exceptional items net of tax and non-controlling interest, as applicable:




Charge/(gain) relating to derivative financial instruments




Hedging contracts

(18)



Convertible Redeemable shares

340



Contingent consideration measured at fair value

317



Tax relief on exercise of share options

(154)



Amortisation of intangible assets

2,897



Acquisition-related transaction costs

716



Relocation costs

120



Utilisation of prior year tax losses

(40)



Basic and diluted profit after tax, excluding exceptional items

5,444







Number of shares for calculation of basic earnings per share including exceptional items


5,417,971


Effect of potential shares


201,205


Number of shares for calculation of diluted earnings per share including exceptional items


5,619,176


Dilutive effect of potential derivative financial instruments


26,068


Number of shares for calculation of diluted earnings per share excluding exceptional items


5,645,244






Basic earnings per share (including exceptional items)



23.4

Diluted earnings per share (including exceptional items)



22.5

Basic earnings per share (excluding exceptional items)



100.5

Diluted earnings per share (excluding exceptional items)



96.4

 

7.         Share issue

 

During the first six months of 2014 the following allotments took place:

 

·        to satisfy the exercise of share options as follows:

§ share options on 27 January 2014 when the mid-market share price was 2,060.0p

§ share options on 10 February 2014 when the mid-market share price was 2,282.5p

§ share options on 29 May 2014 when the mid-market share price was 2,075.0p

§ share options on 5 June 2014 when the mid-market share price was 2,065.0p

 

·        to satisfy the requirements of the earn-out on the acquisition of Scientifica when the mid-market share price was 2,080.0p

 

Ordinary shares in issue are summarised as follows:

 


6 months to June 2014

6 months to June 2013

Year to

31 December

2013


no.

no.

No.





Ordinary shares of 5p each




Issued and fully paid




Beginning of the period

5,862,270

5,312,499

5,312,499

Shares issued as part of the Scientifica earn-out

42,372

-

-

Share placing

-

-

500,000

Exercise of share options

59,100

6,500

49,771

End of the period

5,963,742

5,318,999

5,862,270

 

 

8.         Changes in net debt in the 6 months ended 30 June 2014 were as follows:

 


1 January 2014

Cash flow

Non-cash items

30 June 2014


£000

£000

£000

£000

Cash at bank and in hand

10,054

75

-

10,129

Debt

(15,043)

1,762

19

(13,262)

Net senior debt

(4,989)

1,837

19

(3,133)

Effect of payments relating to the acquisition of Scientifica Limited not settled at 30 June 2014 (included within current liabilities)

(537)

514

-

(23)

Effect of payments relating to the 2012 acquisition of the trade and certain assets of KE Developments Limited not settled at 30 June 2014 (included within current liabilities)

(155)

22

-

(133)

Adjusted net senior debt

(5,681)

2,373

19

(3,289)

Subordinated loans

(497)

-

-

(497)

Total net debt

(6,178)

2,373

19

(3,786)

 

Non-cash items represent foreign exchange differences on bank loans.

 

 

9.         Dividends

 

The Company paid an interim dividend of 6.6p per share (£353,625) on 8 November 2013 and a final dividend of 13.4p per share (£799,141) on 3 July 2014, both relating to the financial year ended 31 December 2013.

 

The Company will pay an interim dividend for 2014 of 7.3p per share on 7 November 2014 to shareholders on the register on 10 October 2014.  The shares will go ex-dividend on 9 October 2014.


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
IR PGUGWBUPCGQW
UK 100

Latest directors dealings